OncoMatch

OncoMatch/Clinical Trials/NCT06934382

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Is NCT06934382 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Allogeneic anti-CD7 CAR-T cells (BEAM-201) for t-cell acute lymphoblastic leukemia/lymphoma.

Phase 1RecruitingStephan Grupp MD PhDNCT06934382Data as of May 2026

Treatment: Allogeneic anti-CD7 CAR-T cells (BEAM-201)This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Lymphoblastic Leukemia

Non-Hodgkin Lymphoma

Biomarker criteria

Required: CD7 expression (at least 90% of blasts positive)

Prior therapy

Must have received: chemotherapy — induction and/or re-induction

second or greater relapse, first relapse post-transplant, or chemotherapy-refractory disease

Cannot have received: CD7 targeted therapy

Receipt of prior CD7 targeted therapy

Cannot have received: radiation therapy

Exception: prophylaxis for CNS disease

Radiation therapy within 2 weeks prior to completion of screening, other than prophylaxis for CNS disease

Lab requirements

Kidney function

Adequate Serum creatinine based on age/gender

Liver function

ALT ≤ 5x ULN in the absence of ALL infiltration of the liver; Bilirubin ≤ 3 × ULN for age (exceptions if abnormalities are directly related to ALL infiltration of the liver)

Cardiac function

ECHO with LVSF ≥ 30% or LVEF ≥ 50%; or qualitative normal ventricular function by cardiologist

Adequate organ function defined as: Adequate Serum creatinine based on age/gender; ALT ≤ 5x ULN in the absence of ALL infiltration of the liver; Bilirubin ≤ 3 × ULN for age... Cardiac echocardiography (ECHO) with left ventricular shortening fraction (LVSF) ≥ 30% or left ventricular ejection fraction (LVEF) ≥ 50%. In cases where quantitative assessment of LVSF/LVEF is not possible, a statement by the cardiologist that the ECHO shows qualitatively normal ventricular function will suffice

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Children's Hospital of Philadelphia · Philadelphia, Pennsylvania

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify